drugset / Trial / NCT05241834

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

NCT05241834

Phase 1 Active not recruiting 70 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24 months (2 years) and possibly longer if the disease does not get worse.

Timeline

Start
2022-03-23
Primary completion
2024-09-17
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject LOXO-260 Unknown Oral